Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Appears To Quickly Renege On Next-Gen COVID Vaccine Guidance With Updated Booster Announcement

Executive Summary

After issuing guidance and making public statements saying the first updated COVID-19 vaccines would require clinical trial data, agency picks new vaccine composition that will make obtaining such data highly unlikely before a planned fall booster campaign. 

You may also be interested in...



Califf’s Covid Twitter Communications Reveal Knowledge Gaps Partially Of FDA’s Own Making

FDA Commissioner’s recent Twitter threads highlight the challenges of discussing the unknowns of therapeutic interventions – and raise questions about why FDA isn’t doing more to close the information gaps.

Next-Gen COVID Vaccines Could Be Awesome – If They Ever Get Made

Mucosal and other new vaccines in development should target infection and transmission prevention, as White House’s Ashish Jha calls for them to be ‘better than terrific.’ But with the market transitioning to a flu-like status, incentives for big investments seem limited.

Next-Gen Vaccine Makers Want Up-Front Discussions With US FDA To Expedite Development

Early conversations on clinical trial endpoints were particularly helpful in developing Comirnaty, a Pfizer executive said. Whether sponsors can continue to get such discussions may go a long way in determining whether a new generation of products is developed.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel